Episode 172: Spinal Muscular Atrophy Awareness Month: Why Multidisciplinary Care Matters
Share
Subscribe
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In episode 172, “Spinal Muscular Atrophy Awareness Month: Why Multidisciplinary Care Matters,” Sandeep Rana, MD, a neurologist specializing in neuromuscular disorders at Allegheny Health Network, discussed the multidisciplinary care model for spinal muscular atrophy (SMA) implemented in his center, in honor of SMA Awareness Month. He described a clinic structure that includes physical and occupational therapists, respiratory therapists, nutritionists, speech therapists, social workers, and collaboration with pulmonologists experienced in neuromuscular disease.
Rana also outlined how the advent of disease-modifying therapies has transformed SMA from a largely fatal illness into a more manageable condition. He highlighted key advancements in therapeutics that have shifted priorities toward long-term wellness, including weight management, physical fitness, and emotional health. He noted persistent challenges in organizing and sustaining a specialized multidisciplinary team. Finally, he emphasized the importance of clinician awareness, early identification, and timely referral to tertiary centers, particularly as additional therapies may become available.
Looking for more neuromuscular disorder discussions? Check out the NeurologyLive® Neuromuscular Disorders clinical focus page.
Episode Breakdown:
- 1:25 – Professional background and clinic overview
- 2:55 – What an effective multidisciplinary SMA care team looks like
- 5:12 – How disease-modifying therapies have changed SMA care
- 6:28 – Neurology News Minute
- 9:27 – Organizational and procedural challenges in coordinating care
- 11:52 – Why raising awareness about SMA is important & advice to clinicians
- 13:45 – Key message about SMA today
The stories featured in this week’s Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- FDA Accepts SL1009 Resubmission for PDCD, Sets December PDUFA Date
- FDA Advisory Committee Votes Against Deramiocel for DMD Cardiomyopathy
- FDA Grants RMAT Designation to Sasineprocel for Parkinson Disease